Researchers hope that identifying the genomic alterations specific to transformed small cell lung cancer (SCLC) can help ...

Topline pivotal Phase 3 firmonertinib data. ArriVent anticipates having topline firmonertinib monotherapy data from the event-driven global pivotal FURVENT Phase 3 (NCT05607550) study in 2025 and ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported ...

The role of EGFR in KRASG12D-driven tumorigenesis was studied using mouse CRC organoids with KRAS-APC-TP53 mutations and ...

Young lung cancer patients have a higher incidence of targetable biomarkers, necessitating comprehensive testing for ALK fusions and EGFR mutations. Repeat biomarker testing is essential when ...

After considering the feedback from consultation, the appraisal committee has prepared final draft guidance (FDG) on osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...